CN114341184A - 抗FcRn抗体、其抗原结合片段及其医药用途 - Google Patents

抗FcRn抗体、其抗原结合片段及其医药用途 Download PDF

Info

Publication number
CN114341184A
CN114341184A CN202180004919.6A CN202180004919A CN114341184A CN 114341184 A CN114341184 A CN 114341184A CN 202180004919 A CN202180004919 A CN 202180004919A CN 114341184 A CN114341184 A CN 114341184A
Authority
CN
China
Prior art keywords
seq
amino acid
nos
acid sequence
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180004919.6A
Other languages
English (en)
Other versions
CN114341184B (zh
Inventor
刘潇
王雷
杜延平
申晨曦
戴宸
吴然
崔妍
胡冬梅
杨阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tuojie Biomedical Technology Co ltd
Original Assignee
Beijing Tuojie Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuojie Biomedical Technology Co ltd filed Critical Beijing Tuojie Biomedical Technology Co ltd
Publication of CN114341184A publication Critical patent/CN114341184A/zh
Application granted granted Critical
Publication of CN114341184B publication Critical patent/CN114341184B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了一种抗FcRn抗体、其抗原结合片段及其医药用途。具体而言，提供了一种抗FcRn抗体、其抗原结合片段、及其治疗自身免疫疾病、炎性病症的医药用途。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202180004919.6A 2020-02-10 2021-02-09 抗FcRn抗体、其抗原结合片段及其医药用途 Active CN114341184B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020100838921 2020-02-10
CN202010083892 2020-02-10
PCT/CN2021/076211 WO2021160116A1 (zh) 2020-02-10 2021-02-09 抗FcRn抗体、其抗原结合片段及其医药用途

Publications (2)

Publication Number Publication Date
CN114341184A true CN114341184A (zh) 2022-04-12
CN114341184B CN114341184B (zh) 2023-04-04

Family

ID=77291390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180004919.6A Active CN114341184B (zh) 2020-02-10 2021-02-09 抗FcRn抗体、其抗原结合片段及其医药用途

Country Status (3)

Country Link
CN (1) CN114341184B (zh)
TW (1) TW202140560A (zh)
WO (1) WO2021160116A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114129730A (zh) * 2021-09-16 2022-03-04 宁夏大学 FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364265A (zh) * 2012-05-14 2015-02-18 Ucb医药有限公司 抗FcRn抗体
CN104479017A (zh) * 2008-04-25 2015-04-01 戴埃克斯有限公司 针对fcrn的抗体及其用途
WO2016142782A1 (en) * 2015-03-09 2016-09-15 Argen-X N.V. Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
CN106103476A (zh) * 2013-12-24 2016-11-09 阿尔金-X有限公司 FcRn拮抗剂及使用方法
CN106459215A (zh) * 2014-04-30 2017-02-22 韩诺生物制药株式会社 治疗自身免疫疾病的结合fcrn的抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104479017A (zh) * 2008-04-25 2015-04-01 戴埃克斯有限公司 针对fcrn的抗体及其用途
CN104364265A (zh) * 2012-05-14 2015-02-18 Ucb医药有限公司 抗FcRn抗体
CN106103476A (zh) * 2013-12-24 2016-11-09 阿尔金-X有限公司 FcRn拮抗剂及使用方法
CN106459215A (zh) * 2014-04-30 2017-02-22 韩诺生物制药株式会社 治疗自身免疫疾病的结合fcrn的抗体
WO2016142782A1 (en) * 2015-03-09 2016-09-15 Argen-X N.V. Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
钱琨等: "抗Fc受体γ链单克隆抗体的研制及生物学特性鉴定", 《细胞与分子免疫学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114129730A (zh) * 2021-09-16 2022-03-04 宁夏大学 FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用

Also Published As

Publication number Publication date
TW202140560A (zh) 2021-11-01
WO2021160116A1 (zh) 2021-08-19
CN114341184B (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
CN106459215B (zh) 治疗自身免疫疾病的结合fcrn的抗体
EP3753951A1 (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP7189211B2 (ja) 血清中のタンパク質の半減期を増加させるための組成物及び方法
CN114341184B (zh) 抗FcRn抗体、其抗原结合片段及其医药用途
CN111375059A (zh) 一种抗gitr抗体药物组合物及其用途
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP7377185B2 (ja) 抗ヒトｔｌｒ７抗体
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
EP4331603A1 (en) Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
CN116554323A (zh) 人源化抗il21抗体的开发和应用
WO2022002249A1 (zh) 抗FXI/FXIa抗体、其抗原结合片段及医药用途
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
TWI836070B (zh) 抗trop-2抗體、其抗原結合片段及其醫藥用途
CN113484526A (zh) 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
CN114075284A (zh) Cd47结合分子及其用途
WO2023236980A1 (zh) 一种pvrig/tigit双特异性抗体药物组合物及其用途
CN116234573A (zh) 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途
TW202241964A (zh) 因子xia抑制劑之抗體及抗原結合肽及其用途
CN115335402A (zh) 特异性抗原结合分子,其制备方法及医药用途
CN115109157A (zh) 抗体或其抗原结合片段，其制备方法及医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant